Basilea Pharmaceutica Opens U.S. Phase III Study On Alitretinoin For The Treatment Of Severe Chronic Hand Eczema
BASEL, SWITZERLAND--(Marketwire - December 17, 2008): Basilea Pharmaceutica Ltd. (SWISS: BSLN) announces that it has opened a clinical phase III study on alitretinoin in the U.S. The "HANDEL" trial (HAND Eczema research of aLitretinoin) is the first ever multi-centered, controlled clinical study for patients with severe chronic hand eczema (CHE) performed in the U.S